Oct. 1, 2020 US 2020/0308308 A1 245

a VL region having the following CDRs:

LC-CDR1 having the amino acid sequence of SEQ ID NO:41

LC-CDR2 having the amino acid sequence of SEQ ID NO:295

LC-CDR3 having the amino acid sequence of SEQ ID NO:43; or

a VH region having the following CDRs:

HC-CDR1 having the amino acid sequence of SEQ ID NO:290

HC-CDR2 having the amino acid sequence of SEQ ID NO:291

HC-CDR3 having the amino acid sequence of SEQ ID NO:278; and

a VL region having the following CDRs:

LC-CDR1 having the amino acid sequence of SEQ ID NO:41

LC-CDR2 having the amino acid sequence of SEQ ID NO:300

LC-CDR3 having the amino acid sequence of SEQ ID NO:43; or

a VH region having the following CDRs:

HC-CDR1 having the amino acid sequence of SEQ ID NO:290

HC-CDR2 having the amino acid sequence of SEQ ID NO:291

HC-CDR3 having the amino acid sequence of SEQ ID NO:278; and

a VL region having the following CDRs:

LC-CDR1 having the amino acid sequence of SEQ

LC-CDR2 having the amino acid sequence of SEQ ID NO:42

LC-CDR3 having the amino acid sequence of SEQ ID NO:43; or

(e)

a VH region having the following CDRs:

HC-CDR1 having the amino acid sequence of SEQ **ID NO:33** 

HC-CDR2 having the amino acid sequence of SEQ ID NO:277

HC-CDR3 having the amino acid sequence of SEQ ID NO:278; and

a VL region having the following CDRs:

LC-CDR1 having the amino acid sequence of SEQ ID NO:41

LC-CDR2 having the amino acid sequence of SEQ **ID NO:42** 

LC-CDR3 having the amino acid sequence of SEQ ID NO:43; or

a VH region having the following CDRs:

HC-CDR1 having the amino acid sequence of SEQ **ID NO:33** 

HC-CDR2 having the amino acid sequence of SEQ ID NO:286

HC-CDR3 having the amino acid sequence of SEQ ID NO:278; and

a VL region having the following CDRs:

LC-CDR1 having the amino acid sequence of SEQ ID NO:41

LC-CDR2 having the amino acid sequence of SEQ ID NO:42

LC-CDR3 having the amino acid sequence of SEQ ID NO:43; or

a VH region having the following CDRs:

HC-CDR1 having the amino acid sequence of SEQ ID NO:244

HC-CDR2 having the amino acid sequence of SEQ ID NO:34

HC-CDR3 having the amino acid sequence of SEQ ID NO:35; and

a VL region having the following CDRs:

LC-CDR1 having the amino acid sequence of SEQ ID NO:41

LC-CDR2 having the amino acid sequence of SEQ ID NO:245

LC-CDR3 having the amino acid sequence of SEQ ID NO:43; or

(h) a VH region having the following CDRs:

> HC-CDR1 having the amino acid sequence of SEQ ID NO:53

> HC-CDR2 having the amino acid sequence of SEQ ID NO:34

> HC-CDR3 having the amino acid sequence of SEQ ID NO:35; and

a VL region having the following CDRs:

LC-CDR1 having the amino acid sequence of SEQ ID NO:41

LC-CDR2 having the amino acid sequence of SEQ ID NO:58

LC-CDR3 having the amino acid sequence of SEQ ID NO:43; or

a VH region having the following CDRs:

HC-CDR1 having the amino acid sequence of SEQ **ID NO:33** 

HC-CDR2 having the amino acid sequence of SEQ ID NO:34

HC-CDR3 having the amino acid sequence of SEQ ID NO:35; and

a VL region having the following CDRs:

LC-CDR1 having the amino acid sequence of SEQ

LC-CDR2 having the amino acid sequence of SEQ ID NO:67

LC-CDR3 having the amino acid sequence of SEQ ID NO:43; or

(j)

a VH region having the following CDRs:

HC-CDR1 having the amino acid sequence of SEQ **ID NO:33** 

HC-CDR2 having the amino acid sequence of SEQ **ID NO:34** 

HC-CDR3 having the amino acid sequence of SEQ ID NO:35; and

a VL region having the following CDRs:

LC-CDR1 having the amino acid sequence of SEQ ID NO:41

LC-CDR2 having the amino acid sequence of SEQ ID NO:42

LC-CDR3 having the amino acid sequence of SEQ ID NO:43.